In Brief: Cholestech
This article was originally published in The Gray Sheet
Executive SummaryCholestech: Files petition with the Centers for Disease Control and Prevention to reclassify the firm's total cholesterol, HDL cholesterol, triglycerides and glucose tests from the "moderately complex" to "waived" category under provisions of the Clinical Laboratory Improvements Amendments of 1988. CDC recently lifted its moratorium on processing in vitro diagnostic test waiver requests ("The Gray Sheet" Jan. 30, p. 4)...
You may also be interested in...
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.
The pharmaceutical industry would lose bid to eliminate PUPSIT but win relaxed WFI in proposed EU GMP Annex I revision.